Loeys–Dietz Syndrome Type 1: Disease-Characteristics Report

Scope and evidence note. Loeys–Dietz syndrome type 1 (LDS1) means TGFBR1-related Loeys–Dietz syndrome. Many publications pool TGFBR1 with TGFBR2 or all LDS genotypes; such findings are labeled “all-LDS” or “mixed cohort” below and should not be interpreted as LDS1-specific frequencies. Evidence comes from aggregated disease resources, human cohorts, primary model studies, and trial registries—not individual electronic health records.

Table: This table provides a compact, knowledge-base-ready summary of Loeys-Dietz syndrome type 1 focused on confirmed TGFBR1-related findings, management-relevant features, and model systems. It also flags where evidence is only available for umbrella LDS or mixed cohorts rather than LDS1 specifically.

1. Disease information

LDS1 is a rare, autosomal-dominant, syndromic heritable thoracic aortic disease caused by a heterozygous pathogenic variant in TGFBR1, encoding transforming growth factor-β receptor type I/ALK5. Its defining risk is progressive, often widespread arterial aneurysm, tortuosity, dissection, and rupture, accompanied variably by craniofacial, skeletal, cutaneous, ocular, pulmonary, gastrointestinal, and allergic manifestations. The same TGFBR1 variant can produce classic syndromic LDS or apparently nonsyndromic thoracic aortic disease, so absence of the classic facial triad does not exclude LDS1. Open Targets links TGFBR1 (ENSG00000106799) to umbrella LDS, supported by ClinGen and human literature including PMIDs 15731757, 16928994, 16799921, 25006744, and 26493799. (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1, laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 5-6)

Identifiers and names

• Disease: Loeys–Dietz syndrome type 1; TGFBR1-related Loeys–Dietz syndrome; LDS1; Loeys–Dietz syndrome, type I.
• OMIM: commonly designated Loeys-Dietz syndrome 1, 609192; causal gene TGFBR1, 190181.
• MONDO: retrieved Open Targets evidence used MONDO:0018954 for umbrella Loeys–Dietz syndrome; a separate LDS1-specific MONDO identifier was not established in the retrieved evidence.
• Orphanet: Loeys–Dietz syndrome is represented at the umbrella level; subtype-specific coding varies by release.
• ICD-10-CM: no uniquely specific LDS1 code; coding generally uses congenital connective-tissue/aortic aneurysm manifestations. ICD-11 includes Loeys–Dietz syndrome under rare developmental/connective-tissue disease, but local coding should be release-verified.
• MeSH: no consistently used LDS1-specific descriptor was verified; literature is indexed under Loeys–Dietz syndrome, aortic aneurysm, and connective-tissue diseases.

The original receptor-related LDS literature is indexed by PMID 15731757 (2005) and subsequent clinical expansion by PMID 16928994 (2006). The retrieved 2019 report illustrates diagnostic under-recognition: a 47-year-old with the novel TGFBR1 NM_004612.2:c.1225T>G, p.(Trp409Gly) first presented with carotid dissection and middle cerebral artery occlusion after sports activity despite mild systemic findings (published October 2019; DOI: https://doi.org/10.1016/j.ejmg.2019.103727). (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1, laterza2019novelpathogenictgfbr1 pages 1-4)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The primary cause is a constitutional/germline heterozygous pathogenic TGFBR1 variant. Most disease-associated substitutions affect conserved residues in the intracellular serine/threonine kinase domain. Nonsense, frameshift, splice-altering, and deletion variants occur but are less common. In vitro, many mutant receptors have reduced canonical signaling capacity; the pathogenic effect is not adequately described as simple haploinsufficiency because Tgfbr1-null heterozygous mice lack the LDS vascular phenotype whereas missense knock-in mice reproduce it. (verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4)

Risk factors

• Genetic: pathogenic/likely pathogenic TGFBR1 variant; affected first-degree relative; de novo variant. Approximately 75% of LDS cases were described as de novo and 25% inherited in the authoritative review, although this estimate is not from an LDS1-only population. Expressivity is broad, and a mildly affected parent may have a severely affected child. Modifier genes are inferred but no validated clinical modifier has been established. (verstraeten2021loeys–dietzsyndrome pages 3-5, verstraeten2021loeys–dietzsyndrome pages 5-6)
• Hemodynamic/environmental: hypertension, heavy isometric exertion, contact trauma, exercise to exhaustion, and stimulant/vasoconstrictor exposure can increase arterial wall stress. The 2019 cerebrovascular case following sports activity is suggestive but does not prove causation. Pregnancy and the postpartum period plausibly increase risk through hemodynamic and hormonal stress, but robust LDS1-specific event rates were unavailable. (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)
• Age/sex: disease can manifest from infancy through adulthood. No reliable LDS1-specific sex difference, ethnic predisposition, or age-specific incidence was identified.

Protective factors

No genetic protective allele is clinically validated. Practical protection is secondary/tertiary: early molecular diagnosis, lifelong imaging, strict blood-pressure control, avoidance of high-strain activity, and timely prophylactic surgery. Losartan was strongly protective in LDS mouse models, but human LDS1 randomized efficacy data remain insufficient. (verstraeten2021loeys–dietzsyndrome pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 8-9)

There is no infectious cause and no established toxin, diet, smoking, alcohol, pollution, or occupational exposure that causes LDS1. These exposures may modify general cardiovascular risk but have not been quantified as LDS1 gene–environment interactions.

3. Phenotypes

Frequencies below are qualitative unless a defensible all-LDS estimate was retrieved.

• Aortic-root dilatation/aneurysm—clinical sign, often silent; congenital, pediatric, or adult onset; progressive and potentially severe. Dissection has occurred at adult aortic diameters as small as 3.7 cm. Suggested HPO: Aortic root dilatation; Thoracic aortic aneurysm; Aortic dissection. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)
• Diffuse arterial tortuosity, aneurysm, dissection, or rupture—particularly head/neck vessels but potentially subclavian, cerebral, coronary, mesenteric, celiac, hepatic, iliac, and the entire aorta. Events have been reported as early as 3 months in all-LDS experience. HPO: Arterial tortuosity; Arterial aneurysm; Carotid artery dissection; Intracranial aneurysm. (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 7-8)
• Cardiac/valvular: mitral-valve prolapse/regurgitation; less consistently bicuspid aortic valve, patent ductus arteriosus, or atrial septal defect. HPO: Mitral valve prolapse; Mitral regurgitation; Bicuspid aortic valve; Patent ductus arteriosus; Atrial septal defect. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)
• Craniofacial: hypertelorism, bifid/broad/long uvula, cleft palate, high-arched palate, craniosynostosis, malar flattening, micrognathia/retrognathia, and dental crowding. Congenital, with severity ranging from subtle uvular change to major craniosynostosis/clefting. HPO: Hypertelorism; Bifid uvula; Cleft palate; High palate; Craniosynostosis; Micrognathia. (verstraeten2021loeys–dietzsyndrome pages 7-8)
• Musculoskeletal: pectus deformity, scoliosis, arachnodactyly, pes planus, joint hypermobility/subluxation, congenital hip dislocation, camptodactyly, clubfoot, hypotonia, cervical-spine anomalies/instability, low bone density, and fracture susceptibility. Across all LDS, structural cervical anomalies were estimated at ~33%, and cervical instability at ≥50%, particularly with severe craniofacial disease. HPO: Pectus excavatum/carinatum; Scoliosis; Arachnodactyly; Pes planus; Generalized joint hypermobility; Camptodactyly; Talipes equinovarus; Cervical spine instability; Reduced bone mineral density. (verstraeten2021loeys–dietzsyndrome pages 7-8)
• Neurologic/neuroradiologic: dural ectasia, rare Chiari I malformation, hydrocephalus, headache/migraine, and cerebrovascular events. Up to 50% of all-LDS patients were reported to experience recurrent headache/migraine. Cognition is usually unaffected. HPO: Dural ectasia; Chiari malformation type I; Hydrocephalus; Migraine. (verstraeten2021loeys–dietzsyndrome pages 6-7, verstraeten2021loeys–dietzsyndrome pages 9-11)
• Ocular: myopia, blue/dusky sclera, exotropia/strabismus, cataract, retinal detachment, and retinal tortuosity. Ectopia lentis is generally absent, helping distinguish LDS from Marfan syndrome. HPO: Myopia; Blue sclerae; Strabismus; Retinal detachment. (verstraeten2021loeys–dietzsyndrome pages 9-11)
• Respiratory: pneumothorax, restrictive disease secondary to skeletal deformity, asthma/allergic obstruction, emphysema, sleep apnea, and airway compression from severe pulmonary-artery enlargement. HPO: Spontaneous pneumothorax; Restrictive lung disease; Asthma; Obstructive sleep apnea. (verstraeten2021loeys–dietzsyndrome pages 9-11)
• Growth/feeding/GI/allergy: infantile feeding difficulty or failure to thrive, constipation, food/environmental allergy, elevated IgE, asthma, eczema, and eosinophilic gastrointestinal disease occur in the broader LDS spectrum. LDS1-specific frequencies were not retrieved.
• Cutaneous: translucent/velvety skin, easy bruising, widened or atrophic scars, and striae may occur; generally less tissue fragility than vascular Ehlers–Danlos syndrome.

Quality of life. LDS1-only patient-reported data are sparse. In a 2024 mixed study of 42 children—36 Marfan and only 6 LDS—mean treadmill time-to-exhaustion was 3.1 SD below norms, and self-reported fatigue explained 48–49% of fitness variance (published March 2024; DOI: https://doi.org/10.1007/s00431-024-05456-z). (warninkkavelaars2024physicalfitnessin pages 1-2)

A Norwegian mixed cohort included 33 adults with LDS and 17 with vascular EDS: 66% received disability benefits, 42% had full-time disability pension, and median work cessation was 41 years; 80% reported chronic pain. These figures cannot be assigned specifically to LDS1. The abstract states that employed participants were “less fatigued…had less sleep problems and higher satisfaction with life” (published December 2022; DOI: https://doi.org/10.1371/journal.pone.0279848). (johansen2022educationandemployment pages 4-6, johansen2022educationandemployment pages 1-2, johansen2022educationandemployment pages 8-9)

4. Genetic and molecular information

TGFBR1 comprises nine exons and encodes a transmembrane serine/threonine kinase receptor. The retrieved 2019 report noted 84 TGFBR1 mutations in HGMD at that time, but this is obsolete and not a current pathogenic-variant count. Pathogenic variants are germline and usually heterozygous. ClinVar classification should be applied variant by variant under ACMG/AMP criteria; a VUS alone does not establish LDS1. (laterza2019novelpathogenictgfbr1 pages 1-4)

Pathogenic LDS1 alleles are expected to be absent or extremely rare in population databases such as gnomAD; no universal allele frequency can be assigned. Missense kinase-domain variants predominate. The best-supported functional model combines impaired receptor output under controlled ligand stimulation with chronic compensation, ligand overproduction, and paradoxical excess pathway output in diseased tissue. A blanket “gain-of-function” or “loss-of-function” annotation is therefore misleading. (verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2)

No reproducible LDS1 modifier gene, founder mutation, anticipation mechanism, disease-specific methylation signature, or recurrent chromosomal abnormality is established. Large deletions/CNVs are possible but much less characteristic than sequence variants. Somatic mutation is not the usual origin. Biallelic TGFBR1-related profound connective-tissue disease has been reported, but classic LDS1 is dominant and monoallelic.

Suggested annotations: HGNC:11772 (TGFBR1); protein TGF-β receptor type I/ALK5; GO concepts transforming growth factor beta receptor signaling pathway, SMAD protein signal transduction, and transmembrane receptor protein serine/threonine kinase activity.

5. Environmental and lifestyle information

Environmental exposure is not etiologic. Management treats mechanical load as a modifier: avoid collision sports, intense isometric exercise, heavy lifting, and exercise to exhaustion; favor individualized moderate dynamic activity after cardiovascular assessment. Avoid tobacco and uncontrolled hypertension as general vascular precautions, although LDS1-specific attributable-risk estimates are unavailable. Decongestants, stimulants, and vasoconstrictive migraine drugs require caution. No pathogen, vector, vaccine, toxin-removal program, or infectious prophylaxis is LDS1-specific. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)

6. Mechanism and pathophysiology

Causal chain: germline TGFBR1 variant → defective receptor kinase signaling in susceptible mesenchymal/vascular lineages → altered vascular smooth-muscle-cell differentiation, organization, and contractility → compensatory TGF-β1 production and progressively increased pSMAD2/3/target-gene activity in vivo → dysregulated ECM synthesis/remodeling, collagen modification, elastin fragmentation, proteoglycan accumulation, and wall thickening → reduced arterial tensile strength/compliance → progressive dilation, tortuosity, aneurysm, dissection, and rupture. Craniofacial, skeletal, palatal, pulmonary, and immune phenotypes reflect TGF-β’s developmental and homeostatic roles in other tissues. (elendu2025geneticfactorsand pages 11-12, gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, yang2024bioengineeredvasculargrafts pages 1-2)

The 2014 knock-in study’s abstract states that aortic-wall signaling showed “progressive upregulation of Smad2 phosphorylation and TGF-β target gene output,” paralleling aneurysm progression (J Clin Invest, January 2014; DOI: https://doi.org/10.1172/JCI69666). Tgfbr1^M318R/+ mice developed enlarged roots, accelerated growth, elastin breaks, excessive collagen, tortuosity, dissection, and shortened survival, whereas simple Tgfbr1 haploinsufficiency did not. Approximately 60% of mouse deaths showed hemothorax or hemopericardium. Losartan protection correlated with reduced pSmad2 and TGF-β1, while hemodynamically comparable propranolol had only a modest growth effect and did not preserve wall architecture. (gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4)

A major 2024 development used gene-edited and patient-derived hiPSC vascular smooth-muscle cells carrying TGFBR1 p.Ala230Thr in bioengineered grafts implanted into nude-rat carotid arteries. Mutant grafts had lower burst pressure and suture-retention strength and dilated in vivo. Spatial transcriptomics identified defective ECM-gene expression; tissue assays showed decreased collagen hydroxylation and disorganized smooth muscle. The authors’ abstract concludes that the work “highlighted the role of reduced collagen modifying enzyme activity in human TAA formation” (Science Translational Medicine, 8 May 2024; DOI: https://doi.org/10.1126/scitranslmed.adg6298). (yang2024bioengineeredvasculargrafts pages 1-2)

Cell/ontology suggestions: vascular smooth-muscle cell (CL), endothelial cell (CL), fibroblast/myofibroblast (CL), leukocyte/CD45-positive immune cell (CL); aorta and aortic root (UBERON); extracellular matrix, plasma membrane receptor complex, cytoplasm, and nucleus (GO cellular components). Relevant biological processes include ECM organization, collagen fibril organization, elastic-fiber assembly, smooth-muscle contraction, response to mechanical stimulus, and TGF-β receptor signaling. No validated LDS1 metabolomic, lipidomic, single-cell atlas, or diagnostic multi-omics signature is currently established.

7. Anatomical structures affected

The primary organ system is cardiovascular: aortic root, ascending/descending thoracic and abdominal aorta, and medium-to-large arteries from head to pelvis. Secondary sites include mitral/aortic valves, pulmonary artery, cerebral and cervical arteries, coronary and visceral branches. Other systems include skull/sutures, palate/uvula, cervical and thoracolumbar spine, thoracic cage, joints, long bones/digits, skin, eyes/retina, dura, lungs/airways, and gastrointestinal tract. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8, verstraeten2021loeys–dietzsyndrome pages 9-11)

At tissue level, the arterial media and adventitia are central, particularly lineage-specific aortic smooth-muscle populations derived from second heart field and neural crest. Relevant subcellular sites are the plasma membrane TGFBR complex, cytoplasmic SMAD signaling machinery, nucleus, and extracellular collagen/elastin matrix. Disease is generally systemic and bilateral rather than lateralized; an individual aneurysm or dissection can be anatomically asymmetric.

8. Temporal development

LDS1 is congenital in genetic origin and lifelong. Craniofacial, palatal, foot, and skeletal abnormalities may be evident prenatally or neonatally. Aortic enlargement can begin in infancy or childhood but may remain clinically silent until adult dissection or stroke. Progression is chronic and highly variable, with abrupt episodic complications superimposed on progressive arteriopathy. No remission is expected. (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 7-8)

Critical intervention windows are: diagnosis before the first vascular event; serial imaging during somatic growth; intensified assessment during rapid aortic enlargement; preconception and pregnancy/postpartum surveillance; and close follow-up after dissection or surgery. After type-B dissection, expert guidance recommends imaging at 7–14 days and 1, 3, 6, and 12 months, then annually if stable. (verstraeten2021loeys–dietzsyndrome pages 8-9)

9. Inheritance and population

Inheritance is autosomal dominant, with a 50% transmission probability per pregnancy for a heterozygous parent. Penetrance is high but may be incomplete and is age-dependent; expressivity is markedly variable. Anticipation is unproven. Parental mosaicism and germline mosaicism are possible explanations for recurrence after an apparently de novo event but are not quantified. Consanguinity is not relevant to ordinary monoallelic LDS1. (verstraeten2021loeys–dietzsyndrome pages 3-5, verstraeten2021loeys–dietzsyndrome pages 5-6)

The estimated prevalence often quoted for all LDS is approximately 1 in 100,000, but this is not a measured LDS1 prevalence and may reflect underdiagnosis. Reliable incidence, carrier frequency, founder effects, geographic clustering, ethnic enrichment, and sex ratio were not identified. LDS occurs globally and in all sexes. (elendu2025geneticfactorsand pages 11-12)

10. Diagnostics

Diagnosis combines phenotype, family history, vascular imaging, and identification of a heterozygous pathogenic/likely pathogenic TGFBR1 variant.

1. Clinical assessment: three-generation pedigree; examination for hypertelorism, uvular/palatal anomaly, craniosynostosis, pectus/scoliosis, joint laxity or contracture, clubfoot, translucent skin, bruising, and allergic/GI manifestations.
2. Imaging: baseline transthoracic echocardiography for root/ascending aorta and valves; contrast CTA or MRA from head through pelvis to detect tortuosity, aneurysm, and dissection. Flexion–extension cervical radiographs assess instability; CT evaluates suspected craniosynostosis; DEXA is reasonable for low density/fracture risk. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)
3. Genetics: a comprehensive heritable thoracic aortic disease panel is preferred over serial single-gene testing because of phenotypic overlap. Panels should include at least TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, TGFB3, FBN1, SKI, COL3A1, ACTA2, MYH11, MYLK, PRKG1, SLC2A10, EFEMP2, FLNA, and BGN as locally appropriate. Add deletion/duplication analysis because some panels incompletely detect CNVs. WES/WGS is appropriate when panel testing is negative or the presentation is atypical. CMA/karyotype/FISH, mitochondrial sequencing, and repeat-expansion testing are not routine unless another diagnosis is suspected. (verstraeten2021loeys–dietzsyndrome pages 5-6)
4. Biomarkers/omics: no validated blood, protein, metabolite, liquid-biopsy, or epigenomic diagnostic test replaces molecular testing and imaging.

Differential diagnosis: Marfan syndrome—ectopia lentis and FBN1, usually less diffuse tortuosity; vascular EDS—COL3A1, greater tissue/organ fragility and rupture without prior dilation; Shprintzen–Goldberg syndrome—SKI plus developmental delay; arterial tortuosity syndrome—biallelic SLC2A10 with generalized tortuosity and stenoses; congenital contractural arachnodactyly—FBN2, crumpled ears and contractures without aggressive aneurysm; cutis laxa—marked loose skin/emphysema; and nonsyndromic HTAD. (verstraeten2021loeys–dietzsyndrome pages 6-7, verstraeten2021loeys–dietzsyndrome pages 5-6)

Cascade testing is recommended for relatives. Prenatal diagnosis and preimplantation genetic testing are feasible once the familial variant is known. LDS1 is not part of routine newborn biochemical screening.

11. Outcome and prognosis

Cardiovascular disease is the major source of morbidity and mortality. Prognosis depends on genotype/variant context, maximum and growth-rate of arterial dimensions, prior dissection, family history, arterial distribution, blood pressure, valve disease, and access to surveillance and prophylactic repair. Exact 5- or 10-year LDS1 survival and life expectancy are not established. Historical descriptions of early rupture should not be translated directly to modern managed patients. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)

Morbidity includes repeated imaging and operations, chronic pain, fatigue, reduced physical participation, orthopedic disability, allergy/GI disease, and psychosocial distress. Surgery reduces risk in the replaced segment but does not eliminate distal dissection or new aneurysm, so lifelong surveillance continues. (verstraeten2021loeys–dietzsyndrome pages 9-11, johansen2022educationandemployment pages 4-6, warninkkavelaars2024physicalfitnessin pages 1-2)

No validated circulating prognostic biomarker exists. Rapid growth, family dissection at small diameter, severe craniofacial features/arterial tortuosity, and prior vascular event favor a more aggressive strategy, although phenotype–risk correlations are imperfect.

12. Treatment

There is no curative or FDA-approved LDS1-specific molecular therapy.

• Antihypertensive pharmacotherapy: an angiotensin-II receptor blocker—commonly losartan—and/or a β-blocker is used to reduce hemodynamic stress. The specialist review describes losartan targets of 2 mg/kg/day in children and at least 100 mg/day in adults as personal practice, not trial-validated universal dosing. Monitor blood pressure, renal function, potassium, bradycardia, and fatigue. ARBs are contraindicated during pregnancy. Suggested NCIT concepts: Losartan; Angiotensin II Receptor Antagonist; Beta-Adrenergic Receptor Antagonist. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)
• Surgery: prophylactic valve-sparing aortic-root replacement is often preferred. For adults with LDS1/LDS2, expert guidance commonly considers surgery around 4.0 cm, individualized downward or upward by body size, growth rate, family history, variant severity, valve regurgitation, and surgical expertise. Rapidly enlarging or markedly disproportionate visceral/iliac aneurysms also merit intervention. Suggested NCIT concepts: Aortic Root Replacement; Valve-Sparing Aortic Root Replacement; Vascular Surgery. (verstraeten2021loeys–dietzsyndrome pages 8-9)
• Supportive care: physical therapy for hypotonia/hypermobility; orthopedic management of scoliosis, cervical instability, and clubfoot; calcium/vitamin-D adequacy and bone-health assessment; standard craniosynostosis/cleft-palate, ophthalmic, pulmonary, allergy, GI, dental, pain, and psychosocial care. (verstraeten2021loeys–dietzsyndrome pages 7-8, verstraeten2021loeys–dietzsyndrome pages 9-11)
• Rehabilitation: individualized low-to-moderate dynamic exercise may counter deconditioning and fatigue, but data are mainly mixed Marfan/LDS cohorts rather than LDS1 trials. (warninkkavelaars2024physicalfitnessin pages 1-2)
• Advanced therapeutics: no retrieved clinical gene-replacement, CRISPR, cell, mRNA, ASO, or siRNA therapy exists for LDS1. The 2024 collagen-modification work is mechanistic, not a clinical treatment. (yang2024bioengineeredvasculargrafts pages 1-2)

Trial landscape: NCT05472519 (I-LoDiS; France; completed June 2023; actual n=60) compared genetically confirmed TGFBR1/TGFBR2 LDS with controls, measuring circulating T-follicular-helper cells, intracellular pSMAD2/3, allergic/infectious disease, and vascular/morphoskeletal complications. It was a blood-sampling immunopathology study, not a therapeutic drug trial. (NCT05472519 chunk 1)

13. Prevention

Primary prevention of the germline disorder is not possible after conception. Reproductive options include genetic counseling, donor gametes, PGT-M, and prenatal diagnosis. Secondary prevention consists of cascade testing and presymptomatic vascular imaging. Tertiary prevention comprises blood-pressure control, avoidance of high-strain activities and tobacco, serial whole-arterial-tree imaging, pregnancy planning, prompt assessment of acute chest/back/abdominal/neurologic symptoms, and prophylactic repair. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)

Recommended expert surveillance includes echocardiography at least annually, more often with active enlargement, and head-to-pelvis MRA/CTA at diagnosis, again after one year, then at least every 2–3 years if stable. These intervals must be individualized. There is no applicable vaccine, infection-control program, population-wide screening program, or preventive dietary supplement beyond ordinary bone/cardiovascular health. (verstraeten2021loeys–dietzsyndrome pages 8-9)

14. Other species and natural disease

No well-established naturally occurring veterinary LDS1 equivalent was identified in the retrieved evidence. TGFBR1 is evolutionarily conserved in mammals, but experimental engineered disease should not be labeled natural animal disease. There is no transmission or zoonotic potential. Relevant taxa for experimental work are Mus musculus (NCBI Taxonomy 10090) and Rattus norvegicus (10116). Breed-specific/VBO associations and an OMIA natural-disease entry were not established.

15. Model organisms and experimental systems

• Tgfbr1^M318R/+ knock-in mouse: mammalian germline knock-in; reproduces progressive aortic-root enlargement, elastin fragmentation, collagen accumulation, arterial tortuosity, dissection, early death, and craniofacial/skeletal findings. It is useful for receptor biology and drug testing. Limitation: mouse size, lifespan, hemodynamics, and developmental lineages differ from humans. (gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4)
• Tgfbr1 haploinsufficient mouse: approximately 50% transcript reduction but no comparable cardiovascular phenotype; a valuable negative model showing that simple dosage loss is insufficient. (gallo2014angiotensinii–dependenttgfβ pages 2-4)
• Patient and isogenic hiPSC-derived VSMCs: model lineage-specific cellular defects and permit genetic correction controls. Limitation: two-dimensional cultures lack full vascular architecture and hemodynamic loading. (yang2024bioengineeredvasculargrafts pages 1-2)
• 2024 bioengineered vascular graft: TGFBR1 p.Ala230Thr patient/isogenic VSMCs formed grafts implanted in nude-rat carotids, combining human genotype with in-vivo mechanical stress. It reproduced dilation, weak mechanics, defective ECM transcription, reduced collagen hydroxylation, and impaired contraction. Limitations include an ectopic carotid location, immunodeficient host, engineered tissue, and concentration on one variant. (yang2024bioengineeredvasculargrafts pages 1-2)

Current expert interpretation and major evidence gaps

The most defensible current model is not simply “too little” or “too much” TGF-β. TGFBR1 variants impair receptor function in controlled cellular assays, while chronic, cell-nonautonomous compensation produces increased ligand/pSMAD signaling in the diseased postnatal vessel. The 2024 human graft study shifts attention downstream toward defective collagen modification and biomechanics, offering a more direct bridge from receptor genotype to wall failure. (gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, yang2024bioengineeredvasculargrafts pages 1-2)

The principal gaps are LDS1-specific prevalence and natural-history estimates, prospective pregnancy data, variant-level risk models, randomized ARB/β-blocker trials, validated circulating biomarkers, representative single-cell/spatial atlases of human aorta, and disease-specific quality-of-life and rehabilitation trials. Consequently, current real-world care remains multidisciplinary and prevention-oriented: molecular confirmation, complete arterial imaging, strict blood-pressure management, tailored activity, and timely surgery.

References

1. (laterza2019novelpathogenictgfbr1 pages 1-4): Domenico Laterza, Marco Ritelli, Andrea Zini, Marina Colombi, Maria Luisa Dell'Acqua, Laura Vandelli, Guido Bigliardi, Luca Verganti, Stefano Vallone, Chiara Vincenzi, Francesca Rosafio, Ludovico Ciolli, Olga Calabrese, Paolo Frigio Nichelli, and Livio Picchetto. Novel pathogenic tgfbr1 and smad3 variants identified after cerebrovascular events in adult patients with loeys-dietz syndrome. European journal of medical genetics, 62:103727, Oct 2019. URL: https://doi.org/10.1016/j.ejmg.2019.103727, doi:10.1016/j.ejmg.2019.103727. This article has 18 citations and is from a peer-reviewed journal.

2. (verstraeten2021loeys–dietzsyndrome pages 3-5): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

3. (gallo2014angiotensinii–dependenttgfβ pages 1-2): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

4. (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1): Open Targets Query (Loeys-Dietz syndrome-TGFBR1, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (verstraeten2021loeys–dietzsyndrome pages 8-9): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

6. (verstraeten2021loeys–dietzsyndrome pages 7-8): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

7. (verstraeten2021loeys–dietzsyndrome pages 5-6): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

8. (gallo2014angiotensinii–dependenttgfβ pages 8-9): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

9. (gallo2014angiotensinii–dependenttgfβ pages 2-4): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

10. (elendu2025geneticfactorsand pages 11-12): Chukwuka Elendu, Tochukwu R. Nzeako, Nwachukwu O. Nwachukwu, Kenneth N. Akpa, Raymond A. Omiko, Petra S. Ayobami-Ojo, Uguru W. Orji, Vivian C. Nwankwo, Kingsley C. Amaefule, Chiamaka S. Chima, Nwafor W. Chika, John O. Olukorode, Praise O. Oloyede, David M. Falade, Temiloluwa E. Fayemi, Chisom P. Ezeamaku-Humphrey, Roshni R. Vansh, Tobechukwu M.O. Enaholo, Lordsfavour I. Anukam, and Osita M. Chukwuneke. Genetic factors and management strategies in aortic health: a literature review of inherited aortopathy. Annals of Medicine and Surgery, 87:598-615, Dec 2024. URL: https://doi.org/10.1097/ms9.0000000000002969, doi:10.1097/ms9.0000000000002969. This article has 9 citations.

11. (yang2024bioengineeredvasculargrafts pages 1-2): Ying Yang, Hao Feng, Ying Tang, Zhenguo Wang, Ping Qiu, Xihua Huang, Lin Chang, Jifeng Zhang, Yuqing Eugene Chen, Dogukan Mizrak, and Bo Yang. Bioengineered vascular grafts with a pathogenic tgfbr1 variant model aneurysm formation in vivo and reveal underlying collagen defects. Science Translational Medicine, May 2024. URL: https://doi.org/10.1126/scitranslmed.adg6298, doi:10.1126/scitranslmed.adg6298. This article has 17 citations and is from a highest quality peer-reviewed journal.

12. (verstraeten2021loeys–dietzsyndrome pages 9-11): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

13. (johansen2022educationandemployment pages 4-6): Heidi Johansen, Gry Velvin, and Ingeborg B. Lidal. Education and employment status among adults with loeys-dietz syndrome and vascular ehlers-danlos syndrome in norway, a questionnaire based study. PLOS ONE, 17:e0279848, Dec 2022. URL: https://doi.org/10.1371/journal.pone.0279848, doi:10.1371/journal.pone.0279848. This article has 4 citations and is from a peer-reviewed journal.

14. (johansen2022educationandemployment pages 1-2): Heidi Johansen, Gry Velvin, and Ingeborg B. Lidal. Education and employment status among adults with loeys-dietz syndrome and vascular ehlers-danlos syndrome in norway, a questionnaire based study. PLOS ONE, 17:e0279848, Dec 2022. URL: https://doi.org/10.1371/journal.pone.0279848, doi:10.1371/journal.pone.0279848. This article has 4 citations and is from a peer-reviewed journal.

15. (warninkkavelaars2024physicalfitnessin pages 1-2): Jessica Warnink-Kavelaars, Lisanne E. de Koning, Annelies E. van der Hulst, Annemieke I. Buizer, Nicole Poissonnier, Laura E. Wijninga, Leonie A. Menke, Laura Muiño Mosquera, Lies Rombaut, and Raoul H. H. Engelbert. Physical fitness in children with marfan and loeys-dietz syndrome: associations between cardiovascular parameters, systemic manifestations, fatigue, and pain. European Journal of Pediatrics, 183:2421-2429, Mar 2024. URL: https://doi.org/10.1007/s00431-024-05456-z, doi:10.1007/s00431-024-05456-z. This article has 4 citations and is from a peer-reviewed journal.

16. (NCT05472519 chunk 1): Immunopathology of Loeys-Dietz Syndrome. Hospices Civils de Lyon. 2022. ClinicalTrials.gov Identifier: NCT05472519

17. (verstraeten2021loeys–dietzsyndrome pages 6-7): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

18. (johansen2022educationandemployment pages 8-9): Heidi Johansen, Gry Velvin, and Ingeborg B. Lidal. Education and employment status among adults with loeys-dietz syndrome and vascular ehlers-danlos syndrome in norway, a questionnaire based study. PLOS ONE, 17:e0279848, Dec 2022. URL: https://doi.org/10.1371/journal.pone.0279848, doi:10.1371/journal.pone.0279848. This article has 4 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• DOI:10.1371/journal.pone.0279848 (abstract only): "less fatigued…had less sleep problems and higher satisfaction with life"
• closest text in source: "Full-time employed and students were younger (p = 0.014), less fatigued (p = 0.035), had less sleep problems (p = 0.028) and higher satisfaction with life (p<0.001) than those who received disability pension"

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• DOI:10.1007/s00431-024-05456-z (5 mentions) - Physical fitness in children with Marfan and Loeys-Dietz syndrome: associations between cardiovascular parameters, systemic manifestations, fatigue, and pain
• shared terms: aortic, tissue

Weighed against this report's own most characteristic terms: disease, dietzsyndrome, clinical, genetic, variant, gene, vascular, lds1, model, type, tgfbr1, human, risk, phenotype, aortic, arterial, include, tissue, receptor, molecular.